Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 1;195(1):1-3.
doi: 10.1164/rccm.201608-1637ED.

Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension

Mark T Gladwin  1   2   3
Affiliations

Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension

Mark T Gladwin. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Current therapies for pulmonary arterial hypertension target prostacyclin, nitric oxide and endothelin-1 signaling pathways. U.S. Food and Drug Administration (FDA)-approved drugs and others in development are shown in the context of the canonical NO, prostacyclin, and endothelin-1 signaling pathways. Reproduced and modified with permission from Reference . 6R-BH4 = sapropterin dihydrochloride, tetrahydrobiopterin; AC = adenylyl cyclase; BH2 = dihydrobiopterin; BH4 = tetrahydrobiopterin; cGMP = cyclic guanosine monophosphate; COX = cyclooxygenase; ECEs = endothelin-converting enzymes; eNOS = endothelial NO synthase; ETA = endothelin receptor type A; ETB = endothelin receptor type B; GTP = guanosine-5′-triphosphate; IP = prostaglandin I2 (prostacyclin); PDE5 = phosphodiesterase 5; PGI2 = prostaglandin I2; sGC = soluble guanylyl cyclase.
See this image and copyright information in PMC

Comment on

References

    1. Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov. 2015;14:623–641. - PubMed
    1. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115:115–130. - PMC - PubMed
    1. Goncharova EA, Gladwin MT, Kawut SM. Update in pulmonary vascular diseases 2014. Am J Respir Crit Care Med. 2015;192:544–550. - PMC - PubMed
    1. Maron BA, Gladwin MT, Simon MA. Update in pulmonary vascular disease 2015. Am J Respir Crit Care Med. 2016;193:1337–1344. - PMC - PubMed
    1. Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272. - PubMed

Publication types

MeSH terms

Substances